49 related articles for article (PubMed ID: 30275195)
1. Increased Soluble PD-L1 Levels in the Plasma of Patients with Epithelial Ovarian Cancer Correlate with Plasma Levels of
Koukourakis MI; Kontomanolis E; Sotiropoulou M; Mitrakas A; Dafa E; Pouliliou S; Sivridis E; Giatromanolaki A
Anticancer Res; 2018 Oct; 38(10):5739-5745. PubMed ID: 30275195
[TBL] [Abstract][Full Text] [Related]
2. Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients.
Pawłowska A; Kwiatkowska A; Suszczyk D; Chudzik A; Tarkowski R; Barczyński B; Kotarski J; Wertel I
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768993
[TBL] [Abstract][Full Text] [Related]
3. Soluble PD-L1 as a diagnostic and prognostic biomarker in resectable gastric cancer patients.
Chivu-Economescu M; Herlea V; Dima S; Sorop A; Pechianu C; Procop A; Kitahara S; Necula L; Matei L; Dragu D; Neagu AI; Bleotu C; Diaconu CC; Popescu I; Duda DG
Gastric Cancer; 2023 Nov; 26(6):934-946. PubMed ID: 37668884
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: A meta-analysis.
Wei W; Xu B; Wang Y; Wu C; Jiang J; Wu C
Medicine (Baltimore); 2018 Jan; 97(3):e9617. PubMed ID: 29504990
[TBL] [Abstract][Full Text] [Related]
5. Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti-PD-1 inhibitor.
Matsuo N; Azuma K; Hattori S; Ohtake J; Kawahara A; Ishii H; Tokito T; Yamada K; Shibata Y; Shimokawaji T; Kondo T; Kato T; Saito H; Yamada K; Sasada T; Hoshino T
Int J Cancer; 2019 Mar; 144(5):1170-1179. PubMed ID: 30307035
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapy for gynecologic cancers: Toward the era of precision medicine.
Basu P; Mukhopadhyay A; Konishi I
Int J Gynaecol Obstet; 2018 Oct; 143 Suppl 2():131-136. PubMed ID: 30306576
[TBL] [Abstract][Full Text] [Related]
7. PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer.
Stenehjem DD; Tran D; Nkrumah MA; Gupta S
Onco Targets Ther; 2018; 11():5973-5989. PubMed ID: 30275703
[TBL] [Abstract][Full Text] [Related]
8. Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the Prognosis.
Meng X; Gao Y; Yang L; Jing H; Teng F; Huang Z; Xing L
Clin Lung Cancer; 2019 Jan; 20(1):48-58. PubMed ID: 30341017
[TBL] [Abstract][Full Text] [Related]
9. Integrin αvβ8-expressing tumor cells evade host immunity by regulating TGF-β activation in immune cells.
Takasaka N; Seed RI; Cormier A; Bondesson AJ; Lou J; Elattma A; Ito S; Yanagisawa H; Hashimoto M; Ma R; Levine MD; Publicover J; Potts R; Jespersen JM; Campbell MG; Conrad F; Marks JD; Cheng Y; Baron JL; Nishimura SL
JCI Insight; 2018 Oct; 3(20):. PubMed ID: 30333313
[TBL] [Abstract][Full Text] [Related]
10. Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer.
Gunda V; Gigliotti B; Ndishabandi D; Ashry T; McCarthy M; Zhou Z; Amin S; Freeman GJ; Alessandrini A; Parangi S
Br J Cancer; 2018 Nov; 119(10):1223-1232. PubMed ID: 30327563
[TBL] [Abstract][Full Text] [Related]
11. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.
Lalani AA; McGregor BA; Albiges L; Choueiri TK; Motzer R; Powles T; Wood C; Bex A
Eur Urol; 2019 Jan; 75(1):100-110. PubMed ID: 30327274
[TBL] [Abstract][Full Text] [Related]
12. Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients.
Camisaschi C; Renne SL; Beretta V; Rini F; Spagnuolo RD; Tuccitto A; Podda MG; Parmiani G; Rivoltini L; Collini P; Castelli C; Luksch R
BMC Cancer; 2018 Oct; 18(1):983. PubMed ID: 30326856
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab-Induced Impressive Response of Refractory Pulmonary Sarcomatoid Carcinoma with Brain Metastasis.
Salati M; Baldessari C; Calabrese F; Rossi G; Pettorelli E; Grizzi G; Dominici M; Barbieri F
Case Rep Oncol; 2018; 11(3):615-621. PubMed ID: 30323751
[TBL] [Abstract][Full Text] [Related]
14. On the Road to Immunotherapy-Prospects for Treating Head and Neck Cancers With Checkpoint Inhibitor Antibodies.
Ward FJ; Dahal LN; Abu-Eid R
Front Immunol; 2018; 9():2182. PubMed ID: 30319637
[TBL] [Abstract][Full Text] [Related]
15. High expression of E-cadherin and Ki-67 associated with functional/dysfunctional phenotypes of tumor-infiltrating lymphocytes among Chinese patients with operable breast cancer.
Wang R; Shi F; Zhao L; Zhao Y; Wu G; Song QK
J Int Med Res; 2018 Dec; 46(12):5219-5227. PubMed ID: 30318965
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline
Helgadottir H; Ghiorzo P; van Doorn R; Puig S; Levin M; Kefford R; Lauss M; Queirolo P; Pastorino L; Kapiteijn E; Potrony M; Carrera C; Olsson H; Höiom V; Jönsson G
J Med Genet; 2020 May; 57(5):316-321. PubMed ID: 30291219
[TBL] [Abstract][Full Text] [Related]
17. Distribution of CD4
Shi F; Chang H; Zhou Q; Zhao YJ; Wu GJ; Song QK
Onco Targets Ther; 2018; 11():6139-6145. PubMed ID: 30288049
[TBL] [Abstract][Full Text] [Related]
18. Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment.
Teh JLF; Aplin AE
Clin Cancer Res; 2019 Feb; 25(3):921-927. PubMed ID: 30287548
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 Mediates Dysfunction in Activated PD-1
Concha-Benavente F; Kansy B; Moskovitz J; Moy J; Chandran U; Ferris RL
Cancer Immunol Res; 2018 Dec; 6(12):1548-1560. PubMed ID: 30282672
[TBL] [Abstract][Full Text] [Related]
20. Multiplex Immuno-Liquid Chromatography-Mass Spectrometry-Parallel Reaction Monitoring (LC-MS-PRM) Quantitation of CD8A, CD4, LAG3, PD1, PD-L1, and PD-L2 in Frozen Human Tissues.
Zhang Q; Salzler R; Dore A; Yang J; Ma D; Olson WC; Liu Y
J Proteome Res; 2018 Nov; 17(11):3932-3940. PubMed ID: 30277784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
